Mouse Anti-Human CD73
- Known as:
- Mouse Antibody toHuman CD73
- Catalog number:
- 129-10168
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Ray Biotech
- Gene target:
- Mouse Anti-Human CD73
Related genes to: Mouse Anti-Human CD73
- Gene:
- NT5E NIH gene
- Name:
- 5'-nucleotidase ecto
- Previous symbol:
- NT5
- Synonyms:
- CD73, eN, eNT, CALJA
- Chromosome:
- 6q14.3
- Locus Type:
- gene with protein product
- Date approved:
- 1989-02-23
- Date modifiied:
- 2016-10-05
Related products to: Mouse Anti-Human CD73
Related articles to: Mouse Anti-Human CD73
- Our study aims to assess the causal association between plasma proteins, immune cell phenotypes and intracerebral hemorrhage (ICH) and explore their downstream biological correlation. - Source: PubMed
Publication date: 2026/04/25
Gu HengBu Yan-SongNiu Jing-JingZhao Hui-MinLi Jia-HeJiang Xiao-TongWu Shu-TongXu Guo-LiYu ShuaiFeng Hong-XuanKong Fan-ZhenWu Guan-Hui - Dilated cardiomyopathy (DCM) is a clinically heterogeneous cardiac disorder characterized by ventricular dilation and systolic dysfunction, with limited options for mechanism-based diagnosis and targeted therapy. Programmed cell death (PCD), encompassing apoptosis, ferroptosis, pyroptosis, and other regulated mechanisms, has been implicated in the pathogenesis of DCM, yet its diagnostic and therapeutic relevance remains incompletely understood. Here, we performed an integrative multi-omics analysis combining bulk and single-cell RNA sequencing datasets to identify PCD-related molecular features associated with DCM. Through differential gene expression, WGCNA, and six machine learning algorithms, eight core genes (AGTR2, GLI2, HRK, IL10, NQO1, NT5E, SFRP1, and STAT4) were identified and used to construct a predictive model evaluated across five independent cohorts. Immune infiltration and consensus clustering revealed two distinct molecular subtypes with differential immune-metabolic signatures. Single-cell analysis demonstrated cell-type-specific expression, particularly in fibroblasts and immune cells. Drug-gene interaction mapping and molecular docking highlighted decitabine and folic acid as potential therapeutic candidates. Expression of key genes was partially validated at the mRNA and protein levels in both human and mouse myocardium. Notably, given that most transcriptomic datasets represent advanced-stage disease, these findings may reflect shared molecular features of cardiac remodeling rather than early disease-specific mechanisms. This study provides insights into PCD-associated molecular alterations in DCM and offers a basis for future research into molecular stratification and therapeutic targeting. - Source: PubMed
Publication date: 2026/05/18
Fan JiliChen LihongShang WentaoWang XiaotongGan TianTan XinSong LaichunBo Xiaohong - Excessive activation of the adenosine A receptor (AR) contributes to chronic neuroinflammation, in part through spatial coupling with the adenosine-generating enzyme CD73, which enables localized adenosine signaling. Coordinated regulation of and across neuropathological conditions supports dual targeting of the CD73/AR axis to constrain maladaptive inflammatory signaling. - Source: PubMed
Publication date: 2026/04/22
Mihajlovic KatarinaDragic MiloradAdzic Bukvic MarijaMartic TeodoraStevanovic IvanaVinit StéphaneBleuzé MarêvaMansart ArnaudAdam LucilleNedeljkovic Nadezda - Ectonucleotidases catalyze the hydrolysis of extracellular nucleotides, maintaining the balance between proinflammatory ATP and immunosuppressive adenosine. In the present study, we developed potent competitive inhibitors of the main ATP-hydrolyzing ectoenzyme nucleoside triphosphate diphosphohydrolase-1 (NTPDase1, CD39) based on 8-butylthio-AMP as a lead structure. Altogether, 88 purine nucleotides and analogs with broad structural modifications were synthesized, 78 of which are new compounds. 8-Substitution of the purine scaffold with bulky residues is essential for high potency and confers metabolic stability. 8-(1-Naphthylthio)--(4-phenylbutyl)-AMP (, PSB-24379) is the most potent CD39 inhibitor of the series ( 77.4 nM), showing ancillary CD73 inhibition ( 240 nM). Docking into a human CD39 homology model rationalized key interactions. PSB-24379 reduced ATP hydrolysis in melanoma and breast cancer cell membranes and partially reverted ATP-mediated effects on T cell activation and proliferation in an ATP-rich environment. These CD39 inhibitors represent high-quality tool compounds with potential as drugs for immunotherapy of cancer. - Source: PubMed
Publication date: 2026/05/01
Bi ChunyangSchwermer FlorianSchäkel LauraMirza SalahuddinBaburi HelayRiziki PatrickSchmies Constanze CWinzer RiekjeIdris RihamRolshoven GeorgSchilling JuliaLuckenbach LeonPelletier JulieBrusoni Luca SvolacchiaAl Hroub HaneenAl Hamwi GhazlLopez VittoriaAhmadsay AresoRaulien LucaSylvester KatharinaSévigny JeanTolosa EvaGuse Andreas HMüller Christa E - Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited therapeutic options. Immune checkpoint inhibitors (ICIs) modestly improve outcomes, but predictive biomarkers are lacking. CD73, an ecto-5'-nucleotidase, generates immunosuppressive adenosine and may attenuate ICI efficacy. - Source: PubMed
Publication date: 2026/04/25
Saiki MasafumiInoue TomohiroTakusagawa KazuhoHomma KentaFuruya SatoshiShimamura SoOmori ChisaIde ShuichiroHoshino YukiUchida YoshinoriYamaguchi YoheiIkemura ShinnosukeKondo TetsuoSoejima Kenzo